We describe the first clinical application of T-cell-recruiting bispecific antibodies directly into the tumor without the need to preactivate the effector cells. In a Phase I clinical trial, 10 patients with low-grade B-cell lymphoma were treated by a single locoregional injection of CD3؋CD19 bispec
✦ LIBER ✦
Locoregional treatment of low-grade B-cell lymphoma with CD3×CD19 bispecific antibodies and CD28 costimulation: II. Assessment of cellular immune responses
✍ Scribed by Oliver Manzke; Hans Tesch; Johann Lorenzen; Volker Diehl; Heribert Bohlen
- Book ID
- 111697621
- Publisher
- John Wiley and Sons
- Year
- 2001
- Tongue
- French
- Weight
- 193 KB
- Volume
- 91
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
Locoregional treatment of low-grade B-ce
✍
Oliver Manzke; Hans Tesch; Peter Borchmann; Jürgen Wolf; Klaus Lackner; Axel Gos
📂
Article
📅
2001
🏛
John Wiley and Sons
🌐
French
⚖ 240 KB
CD3×CD19 bispecific antibodies and CD28
✍
Oliver Manzke; Sandra Titzer; Hans Tesch; Volker Diehl; H. Bohlen
📂
Article
📅
1997
🏛
Springer-Verlag
🌐
English
⚖ 223 KB
Effect of tetravalent bispecific CD19×CD
✍
Uwe Reusch; Fabrice Le Gall; Manfred Hensel; Gerhard Moldenhauer; Anthony D. Ho;
📂
Article
📅
2004
🏛
John Wiley and Sons
🌐
French
⚖ 284 KB
## Abstract To develop an effective antitumor immunotherapy for B‐lineage non‐Hodgkin's lymphoma, we constructed a tetravalent tandem diabody (tanDb) specific for both human CD19 (B‐cell marker) and CD3 (T‐cell antigen). Here, we report the effective killing of malignant primary B cells from patien